Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Omeprazole

FDA-approved product (capsule, delayed rel pellets, oral), marketed as Omeprazole, Prilosec, Omeprazole Magnesium and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Omeprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Duodenal ulcer
  • Dyspepsia
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Infection
  • Peptic ulcer
  • Peptic ulcer disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Proton pump inhibitors
FDA pharmacologic class
Proton Pump Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Omeprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Omeprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

    NCT01792700 · start 2003-01

    Registered record
    Registry ID
    NCT01792700
    Conditions
    Helicobacter Infections
    Interventions
    esomeprazole; tripotassium dicitrate bismuthate; metronidazole; tetracycline; moxifloxacin; amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    2010-12
    Enrolment
    648

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Infections
    Interventionesomeprazole; tripotassium dicitrate bismuthate; metronidazole; tetracycline +2 more
    PhasePhase 4
    Registry statusCompleted

  • Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

    NCT00241553 · start 2001-04

    Registered record
    Registry ID
    NCT00241553
    Conditions
    NSAIDs; Upper GI Symptoms
    Interventions
    Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-04
    Completion
    2003-02
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSAIDs; Upper GI Symptoms
    InterventionEsomeprazole
    PhasePhase 3
    Registry statusCompleted

  • Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma

    NCT00201422 · start 1996-06

    Registered record
    Registry ID
    NCT00201422
    Conditions
    MALT Lymphoma
    Interventions
    Omeprazole, Amoxicillin, Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1996-06
    Completion
    2004-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMALT Lymphoma
    InterventionOmeprazole, Amoxicillin, Clarithromycin
    PhaseNot applicable
    Registry statusCompleted

  • Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach

    NCT00003617 · start 1995-03

    Registered record
    Registry ID
    NCT00003617
    Conditions
    Gastric Cancer
    Interventions
    chlorambucil; clarithromycin; omeprazole; tinidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    1995-03
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    Interventionchlorambucil; clarithromycin; omeprazole; tinidazole
    PhasePhase 3
    Registry statusUnknown

  • Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)

    NCT02039869

    Registered record
    Registry ID
    NCT02039869
    Conditions
    Gastroesophageal Reflux Disease; Non Erosive Reflux Disease; Dyspepsia
    Interventions
    Confocal endomicroscopy; Proton pump inhibitor; Sucralfate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease; Non Erosive Reflux Disease; Dyspepsia
    InterventionConfocal endomicroscopy; Proton pump inhibitor; Sucralfate
    PhaseNot applicable
    Registry statusWithdrawn